Reassuring long-term data on efficacy and safety of pegvisomant monotherapy in a large series of patients with acromegaly.

Kasuki L, Heck A

Open source

DOI
10.1007/s11102-026-01708-3
Published
2026 Jun 14
Container
Pituitary
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s11102-026-01708-3,
  title = {Reassuring long-term data on efficacy and safety of pegvisomant monotherapy in a large series of patients with acromegaly.},
  author = {Kasuki L and Heck A},
  year = {2026},
  journal = {Pituitary},
  doi = {10.1007/s11102-026-01708-3},
  url = {https://doi.org/10.1007/s11102-026-01708-3}
}

RIS

TY  - JOUR
TI  - Reassuring long-term data on efficacy and safety of pegvisomant monotherapy in a large series of patients with acromegaly.
AU  - Kasuki L
AU  - Heck A
PY  - 2026
JO  - Pituitary
DO  - 10.1007/s11102-026-01708-3
UR  - https://doi.org/10.1007/s11102-026-01708-3
ER  - 

APA

L, K., & A, H. (2026). Reassuring long-term data on efficacy and safety of pegvisomant monotherapy in a large series of patients with acromegaly.. Pituitary. https://doi.org/10.1007/s11102-026-01708-3

Source records